FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1726-1731 December 11, 1997 Number 24 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Optimal therapy to prevent late occlusion of arterial bypass grafts in the legs has not been determined. We assessed the effect of ticlopidine, an inhibitor of platelet aggregation, on the long-term patency of saphenous-vein bypass grafts for the treatment of peripheral vascular disease.

Methods A total of 243 patients with femoropopliteal or femorotibial saphenous-vein bypass grafts were randomly assigned to receive either ticlopidine (250 mg twice a day) or matching placebo for two years. The primary end point was graft patency at two years, as assessed by physical examination, measurement of the ankle brachial index, and duplex ultrasonography or arteriography. The incidence of death and major ischemic events was also analyzed in the two groups.

Results After two years, 66.4 percent of the patients were alive with a patent graft in the ticlopidine group, as compared with 51.2 percent in the placebo group (95 percent confidence interval for the difference between the two groups, 2.9 to 27.4 percent; P = 0.02). The two-year cumulative patency rate was 82 percent in the ticlopidine group and 63 percent in the placebo group (P = 0.002). There was no significant difference between groups in overall mortality or major ischemic events.

Conclusions Ticlopidine significantly improved the long-term patency of saphenous-vein bypass grafts in the legs. Since the drug was well tolerated, its use can be recommended after peripheral-vein bypass surgery.

Source Information

From the Department of Vascular Surgery, Centre Hospitalier Universitaire Henri Mondor, 51 ave. De Lattre de Tassigny, 94000 Créteil, France, where reprint requests should be addressed to Dr. Becquemin.

Full Text of this Article

Related Letters:

Antiplatelet Therapy and Patency of Saphenous-Vein Bypass Grafts in the Legs
Conte M. S., Belkin M., Donaldson M. C., Whittemore A. D., Becquemin J.-P.
Extract | Full Text  
N Engl J Med 1998; 338:1387-1388, May 7, 1998. Correspondence

This article has been cited by other articles:

• Henke, P. K. (2008). Wiviott, Braunwald, McCabe, et al. Prasugrel versus clopidogrel in patients with acute coronary symptoms. N Engl J Med. 2007;357:2001-2015. PERSPECT VASC SURG ENDOVASC THER 20: 223-224  
• Sobel, M., Verhaeghe, R. (2008). Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 815S-843S [Abstract] [Full Text]  
• Clagett, G. P., Sobel, M., Jackson, M. R., Lip, G. Y. H., Tangelder, M., Verhaeghe, R. (2004). Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 609S-626S [Abstract] [Full Text]  
• Smout, J. D., Mikhailidis, D. P., Shenton, B. K., Stansby, G. (2004). Combination Antiplatelet Therapy in Patients with Peripheral Vascular Bypass Grafts. CLIN APPL THROMB HEMOST 10: 9-18 [Abstract]  
• Kugler, C. F., Rudofsky, G. (2003). The challenges of treating peripheral arterial disease. Vasc Med 8: 109-114 [Abstract]  
• Jaff, M. R. (2002). Pharmacotherapy for Peripheral Arterial Disease: Emerging Therapeutic Options. ANGIOLOGY 53: 627-633 [Abstract]  
• Mozes, G., Gloviczki, P. (2002). Adjuvant Therapy in Lower Extremity Revascularization: Prevention of Early and Intermediate Failures. PERSPECT VASC SURG ENDOVASC THER 15: 161-180 [Abstract]  
• Verheugt, F. W.A., Bhatt, D. L., Chew, D. P., Topol, E. J., Hirsch, A. T., Hacke, W., Ringleb, P. A. (2001). Clopidogrel Versus Aspirin After Cardiac Surgery Response. Circulation 104 : e76-e76 [Full Text]  
• Jackson, M. R., Clagett, G. P. (2001). Antithrombotic Therapy in Peripheral Arterial Occlusive Disease. Chest 119: 283S-299S [Full Text]  
• Monagle, P., Michelson, A. D., Bovill, E., Andrew, M. (2001). Antithrombotic Therapy in Children. Chest 119: 344S-370S [Full Text]  
• Paradiso-Hardy, F. L., Angelo, C. M., Lanctot, K. L., Cohen, E. A. (2000). Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ 163: 1441-1448 [Abstract] [Full Text]  
• Quinn, M. J., Fitzgerald, D. J. (1999). Ticlopidine and Clopidogrel. Circulation 100: 1667-1672 [Abstract] [Full Text]  
• Chen, D. K., Kim, J. S., Sutton, D. M. C. (1999). Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine Use: A Report of 3 Cases and Review of the Literature. Arch Intern Med 159: 311-314 [Abstract] [Full Text]  
• Harker, L. A., Marzec, U. M., Kelly, A. B., Chronos, N. R. F., Sundell, I. B., Hanson, S. R., Herbert, J.-M. (1998). Clopidogrel Inhibition of Stent, Graft, and Vascular Thrombogenesis With Antithrombotic Enhancement by Aspirin in Nonhuman Primates. Circulation 98: 2461-2469 [Abstract] [Full Text]  
• Conte, M. S., Belkin, M., Donaldson, M. C., Whittemore, A. D., Becquemin, J.-P. (1998). Antiplatelet Therapy and Patency of Saphenous-Vein Bypass Grafts in the Legs. NEJM 338: 1387-1388 [Full Text]  
• (1998). Ticlopidine Enhances Patency of Leg Bypass Grafts. Journal Watch Cardiology 1998: 6-6 [Full Text]  
• (1997). TICLOPIDINE AFTER LOWER EXTREMITY BYPASS GRAFTING. JWatch General 1997: 4-4 [Full Text]